Loading...
Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis
Revusiran is a 1st-generation short interfering RNA targeting transthyretin conjugated to an N-acetylgalactosamine ligand to facilitate delivery to hepatocytes via uptake by the asialoglycoprotein receptors. Revusiran, in development for the treatment of hereditary transthyretin-mediated amyloidosis...
Na minha lista:
| Udgivet i: | Nucleic Acid Ther |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Mary Ann Liebert, Inc., publishers
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6987735/ https://ncbi.nlm.nih.gov/pubmed/31821125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/nat.2019.0796 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|